FOSTER CITY, CA--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial...
Bioinformatics on the Brink (The Scientist)
News | 12. 20. 2004
Companies struggle to diversify after disappointing software sales sink the sector.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.